Martin Shkreli (AP Images)
January 20, 2023 02:20 PM ESTUpdated January 23, 07:57 AM
Pharma
Law

Mar­tin Shkre­li is back in the crosshairs of the fed­er­al gov­ern­ment for not stay­ing out of phar­ma

Zachary Brennan

Senior Editor

Mar­tin Shkre­li made a name for him­self for goug­ing the price of Dara­prim by 4,000%, say­ing he should’ve raised it even high­er, and then fac­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times